FTO Stabilizes MIS12 to Inhibit Vascular Smooth Muscle Cell Senescence in Atherosclerotic Plaque
DOI: https://doi.org/10.2147/jir.s447379
IF: 4.5
2024-03-20
Journal of Inflammation Research
Abstract:Jingzhao Sun, 1 Mengqi Wang, 2 Fengming Jia, 2 Jiantao Song, 2 Jinlin Ren, 2 Bo Hu 2 1 Department of Emergency, Shandong Provincial Hospital, Shandong University, Jinan, Shandong, 250021, People's Republic of China; 2 Department of Emergency, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, 250021, People's Republic of China Correspondence: Bo Hu, Department of Emergency, Shandong Provincial Hospital Affiliated to Shandong First Medical University, No. 324, Jingwu Road, Jinan, Shandong, 250021, People's Republic of China, Email Purpose: Atherosclerosis is the main cause of atherosclerotic cardiovascular disease (CVD). Here, we aimed to uncover the role and mechanisms of fat mass and obesity-associated genes (FTO) in the regulation of vascular smooth muscle cell (VSMC) senescence in atherosclerotic plaques. Methods: ApoE −/− mice fed a high-fat diet (HFD) were used to establish an atherosclerotic animal model. Immunohistochemistry, and the staining of hematoxylin-eosin, Oil Red O, Sirius red, and Masson were performed to confirm the role of FTO in atherosclerosis in vivo. Subsequently, FTO expression in primary VSMCs is either upregulated or downregulated. Oxidized low-density lipoprotein (ox-LDL) was used to treat VSMCs, followed by EdU staining, flow cytometry, senescence-associated β-galactosidase (SA-β-gal) staining, immunofluorescence, telomere detection, RT-qPCR, and Western blotting to determine the molecular mechanisms by which FTO inhibits VSMC senescence. Results: Decreased FTO expression was observed in progressive atherosclerotic plaques of ApoE −/− mice fed with HFD. FTO upregulation inhibits atherosclerotic lesions in mice. FTO inhibits VSMC aging in atherosclerotic plaques by helping VSMC withstand ox-LDL-induced cell cycle arrest and senescence. This process is achieved by stabilizing the MIS12 protein in VSMC through a proteasome-mediated pathway. Conclusion: FTO inhibits VSMC senescence and subsequently slows the progression of atherosclerotic plaques by stabilizing the MIS12 protein. Keywords: vascular smooth muscle cell, FTO, HFD, senescence, MIS12 protein Atherosclerosis is a chronic disease that is widely distributed worldwide and is characterized by high incidence and mortality rates. Vascular smooth muscle cells (VSMCs) are the basic components of arterial stromal cells and fibrous caps. The continuous accumulation of atherosclerotic plaques in the intima of large and medium-sized arteries leads to vascular stenosis, which restricts blood flow and causes severe tissue hypoxia. 1 Senescent VSMCs accumulate during atherosclerosis and drive plaque progression. 2 VSMCs from human atherosclerotic plaques show lower proliferation levels and higher p21 and p16 expression levels, as well as increased senescence associated beta-galactosidase (SA-β-gal) activity, compared to cells from healthy arterial medium. 3 In atherosclerotic plaques of patients with ischemic heart disease, abdominal aortic aneurysm, and peripheral artery disease, a large number of senescent VSMCs accumulated, 4 and approximately 20% of VSMCs present age-related markers in the carotid artery plaques. 5 In addition, VSMCs from atherosclerotic fibrous caps had shorter telomeres than normal ones. 6 Therefore, studying VSMC senescence can help to elucidate the detailed mechanisms underlying the occurrence of arterial sclerosis. The fat mass and obesity-associated gene (FTO) was one of the earliest genes found in the human genome, and its function is associated with obesity, lipid metabolism, and energy regulation. 7 Current research suggests that FTO gene polymorphisms may be involved in the pathogenesis of metabolic diseases, such as obesity, weight gain, and diabetes. 8 Initially, FTO was thought to be related only to human body fat content, body mass index (BMI), and other indicators. However, recent evidence has shown that the FTO gene-encoded protein is a key regulator of metabolic processes, such as energy metabolism, appetite regulation, insulin sensitivity, glucose, and fatty acid metabolism. 8–10 Additionally, studies have found associations between FTO gene variations and cognitive ability, neurodevelopment, and personality traits. 11,12 Recent studies have demonstrated a relationship between FTO expression and atherosclerosis. Prospective or retrospective cohort studies have found that FTO gene polymorphisms (rs1421085, rs17817449, and rs1121980) are associated with an increased risk of atherosclerosis. 13 FTO gene polymorphisms are significantly correlated with atherosclerosis- -Abstract Truncated-
immunology